- Conditions
- Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation
- Interventions
- Vorasidenib
- Drug
- Lead sponsor
- Institut de Recherches Internationales Servier (I.R.I.S.)
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–1
of 1
matching trial from the live ClinicalTrials.gov search.
Filters: Condition: Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation Clear all